Joseph Vento, MD, MS

@utswcancer showing up @ASCO #GU26! Our team keeps growing. Thanks @QianJanieQin gathering us this AM! W @CharlesJiangMD @JBrugarolas @JVentoMD #KevinCourtney et al Not pictured @SuzanneColeMD @HHammersMD @ndesai2005 #YairLotan

Look at some of the impact of DOD CDMRP funding. @BraunMDPhD is presenting the personalized vaccine in RCC published in @Nature. Please restore funding. It went from $50 Million to $0 Dollars. We have not solved cancer yet! @kidneycan #KCRS25

@TumorBoardTues @brian_rini @IntegrityCE @DrRanaMcKay @montypal @katy_beckermann @JVentoMD @mzugman @DrChoueiri @tompowles1 @TiansterZhang @kidneycan @CParkMD @JadChahoud @alantanmd @Uromigos @AlbigesL @SoaresAndrey @dsahil320 @chefaleixomd @JBrugarolas @YuWeiChenMD @HHammersMD 11//17 #TumorBoardTuesday 👨🏽‍🏫Mini Tweetorial 9👨🏽‍🏫 HIFi causes ⬇️ EPO, anemia🩸 most common AE, G3 ~33% 🫁 Hypoxia, AE of interest (G3 ~11%), mechanism is unclear. ⏱️Median time for both AEs ~ 1 month. 🔡 Mgmt: 💉 ESAs (anemia), oxygen (hypoxia), and ⬇️ dose.

As much as #ASCO25 is about building new connections, it’s also about fostering old ones #NoNewFriends @JVentoMD @catherine_fahey @EricLanderMD

Of pts on #PDIGREE, 23% had IMDC poor risk, with fewer (21%) treated in step 2. Simillarly, 27.7% had bone mets, with fewer (24.5%) treated in step 2. These were statistically significant & can guess why poor risk dz do not do as well w/ 1L ipi/nivo. #ASCO25 @OncoAlert 4/n

🚨Hot off the press: A simultaneous publication in @JCOOP_ASCO alongside @vpatelmd’s presentation highlighting the 1st cluster randomized study evaluating podcasts for heme/onc education! The outcome: @TheFellowOnCall and @TwoOncDocs should be included for h/o fellow education!

Congratulations to all @ASCO @ConquerCancerFd #CDA & #YIA recipients! @CarlosArteagaMD @suzanneconzenmd @andyzwang & I are super proud of @CharlesJiangMD @utswcancer @UTSWHemeOnc — He is one to watch - doing great work with outcomes & trial access for our patients! #ASCO25

Congratulations to our one of a kind #AI #kidneycancer @KCPUTSW @UTSWcomps team with David Hein, Alana Christie, Bing Xie,@JVentoMD @jamieson_ai @PayalKapur5 on @npjDigitalMed #LLM paper rdcu.be/enlxw

Neat experience getting to speak about non-clear cell RCC subtypes after authoring a review with stellar UTSW mentors @QianJanieQin @TiansterZhang @PayalKapur5 @JBrugarolas @HHammersMD Review link: mdpi.com/2072-6694/17/9…

📢 Informatics will lead oncology into the future 📊 Thanks to amazing support from @UTSWHemeOnc, I am pursuing a unique integrated fellowship in heme/onc & clinical informatics @CIC_UTSW! 👨‍💻🩺 RobTurer @JVentoMD @WaddahArafat @littlejonesmd @TimothyJBrownMD @TheCodingDocs

Where is Genitourinary Cancers treatment headed next? Find out at the #OncLive State of the Science Summit™ with @HHammersMD, @JVentoMD, @QianJanieQin, @WaddahArafat, Jue Wang, MD, and Yair Lotan, MD. 🔗 Register Now: hubs.li/Q03hf0W00 @utswcancer #GUCancers

Trying to keep up with all the recent @kidneycancer biomarker developments? Check out our new review for all the latest updates. @brian_rini @VUMCDiscoveries pubmed.ncbi.nlm.nih.gov/40240621/

Our @ASCO update on PARPi+ARPI therapy in BRCA-mut mHRPC: shorturl.at/GOAGA @TiansterZhang Why diff in combo vs seq crossover in BRCAAway? Small n but fascinating results! shorturl.at/D1hVU Ongoing PARPi combo trials in mHSPC including HARMONY led by @QianJanieQin

Check our manuscript just published at @OncJournal Clinical & pathological outcomes of pts undergoing consolidative CN after ICI-based therapy for met / locally advanced RCC. Link: academic.oup.com/oncolo/article… @brian_rini @katy_beckermann @UroCancerMD @DanBarocas @AmyLuckenbaugh

Great Wood fellow case presentations started by @d_shapiro1 at UT Christopher G Wood Austin conference with @JVentoMD @VikramNarayan Dr Justin Matalay Dr Amy Lim @McAGES Dr Christine Ibilibor @OncHahn @patrickpilie. Chris’s memory and spirit was well represented

1/7 🚨 Newly published @JAMAOnc! Deep dive into strategies for RCC patients progressing on ICIs 🚨 A comprehensive review on the latest data and emerging approaches. Read here: 🧵👇jamanetwork.com/journals/jamao… #RCC #Immunotherapy #JAMAOncology

Officially boarded in Medical Oncology 🧬 and Clinical Informatics 💻! After years of alternating focus between clinical and technical training it’s awesome to now be working at the intersection of these fields. @utswcancer @Parkland @CIC_UTSW @KCPUTSW

The Vanderbilt GU Program is looking for new faculty members. Clinical investigators with an interest in translational investigator-initiated trials across GU malignancies are preferred. Message me /@alantanmd for more details! Come work with stellar faculty in an amazing city!

You've heard of the nine circles of Hell? A patient with cancer documented the TWENTY-SIX steps necessary to get their medication (as an oncologist I know a vicious cycle when I see one)

@realbowtiedoc Honored to be part of the team!